Trials / Completed
CompletedNCT01264783
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Revalesio Corporation · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RNS60 | RNS60 for intravenous administration |
| DRUG | Placebo | 0.9% normal saline for injection |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-12-22
- Last updated
- 2011-10-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01264783. Inclusion in this directory is not an endorsement.